The EGFR C797S mutation in TKI-naive NSCLC

The EGFR C797S mutation in TKI-naive NSCLC - de novo EGFR C797S mutation in NSCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029017

Enrollment

244

Registered

2017-09-05

Start date

2018-02-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients who was undergone lung resection or tumor biopsy at Fukushima Medical University Hospital between January 207 and December 2015. 2) Pathologically confirmation of primary non small cell lung cancer 3)EGFR mutation had been examined, and confirmed as follows; G719 mutation, Exon 19 deletion, S768I mutation, T790M mutation, L858R mutation, or L861Q mutation 4) Written informed consent

Exclusion criteria

Exclusion criteria: EGFR-TKI administration before specimen collection

Design outcomes

Primary

Measure	Time frame
Frequency of EGFR-C797S mutation in EGFR TKI naive NSCLC	—

Secondary

Measure	Time frame
EGFR-T790M mutation, allelic pattern of T790M and C797S mutation, clinicopathological features, HER2 amplification, and MET amplification	—

Countries

Japan

Contacts

Public ContactTakumi Yamaura

Fukushima Medical University Department of Chest Surgery

tkm-ymur@fmu.ac.jp(+81)24-547-1252

Outcome results